A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Safety and Efficacy of IGV-001, an Autologous Cell Immunotherapy With Antisense Oligonucleotide (IMV-001) Targeting IGF-1R, in Newly Diagnosed Patients With Glioblastoma

The purpose of this study is to assess progression-free survival (PFS) and overall survival (OS) in newly diagnosed Glioblastoma (GBM) participants treated with IGV-001 as compared with placebo.

Start Date20 Mar 2023

Sponsor / Collaborator

ImVax, Inc.Startup

NCT02507583 / CompletedPhase 1IIT

Phase I Study in Humans Evaluating the Safety of Rectus Sheath Implantation of Diffusion Chambers Encapsulating Autologous Malignant Glioma Cells Treated With Insulin-like Growth Factor Receptor-1 Antisense Oligodeoxynucleotide (IGF-1R/AS ODN) in 32 Patients With Newly Diagnosed Malignant Glioma

This human Phase 1 trial is a continuation of a Phase 1 trial which enrolled patients with recurrent gliomas (#TJU-14379-101) and which was designed after a previously conducted Phase 1 human trial at our institution. With certain modifications, it is intended to reproduce the safety results of the recurrent glioma previous trials as well as explore any objective clinical responses in newly diagnosed patients. Protocol 14379-101 is closed to accrual and Abbreviated Clinical Report is prepared for FDA submission. The safety profile for this protocol was quite favorable.
This treatment involves taking the patient's own tumor cells at surgery, treating them with an investigational new drug (an antisense molecule) designed to shut down a targeted surface receptor protein, and re-implanting the cells, now encapsulated in small diffusion chambers the size of a nickel in the patient's abdomen within 24 hours after the surgery. Loss of the surface receptor causes the tumor cells to die in a process called apoptosis. As the tumor cells die, they release small particles called exosomes, each full of tumor antigens. The investigators believe that these exosomes as well as the presence of the antisense molecule work together to activate the immune system against the tumor as they slowly diffuse out of the chamber. Immune cells are immediately available for activation outside of the chamber because a wound was created to implant these tumor cells and a foreign body (the chamber) is present in the wound. In this trial, a dose escalation of the therapeutic agent will involve an increase in both biodiffusion chamber number as well as the time the biodiffusion chambers remain implanted. The wound and the chamber fortify the initial immune response which eventually leads to the activation of immune system T cells that attack and eliminate the tumor. By training the immune system to recognize the tumor, the patient is also protected through immune surveillance from later tumor growth should the tumor recur. Compared to treatment alternatives for tumor recurrence, including a boost of further radiation and more chemotherapy, this treatment represents potentially greater benefit with fewer risks.

Start Date01 Sep 2015

Sponsor / Collaborator

Thomas Jefferson University

NCT02064829 / CompletedNot Applicable

An Open-label, Randomized, Multi-center, Single-Dose, 2-Sequence, 2-Period, Crossover, Comparative Bioequivalence Study of IG-001 (Cb-paclitaxel) 260 mg/m2 Versus Nab-paclitaxel 260 mg/m2 Administered Intravenously With an Open-Label Extension of IG-001 in Patients With Metastatic or Locally Recurrent Breast Cancer

The purpose of this study is to demonstrate bioequivalence of IG-001 versus nab-paclitaxel in female patients with metastatic or locally recurrent breast cancer. In addition, the study will compare the safety and tolerance of IG-001 and nab-paclitaxel during the bioequivalence 2-period crossover portion of the study. The study will also evaluate the long-term safety of IG-001 over repeated cycles, up to 4 additional cycles of administration.

Start Date01 Mar 2014

Sponsor / Collaborator

Sorrento Therapeutics, Inc.

100 Clinical Results associated with IGV-001

100 Translational Medicine associated with IGV-001

100 Patents (Medical) associated with IGV-001

Literatures (Medical) associated with IGV-001

01 Mar 2024·Future oncology (London, England)

Autologous Cell Immunotherapy (IGV-001) with IGF-1R Antisense Oligonucleotide in Newly Diagnosed Glioblastoma Patients

Article

Author: Ramakrishna, Rohan ; Schulder, Michael ; Brennan, Cameron ; Wong, Eric T ; Pennock, Gregory K ; Zuccarello, Mario ; Elder, J Bradley ; Agarwal, Vijay ; Aulakh, Sonikpreet ; Judy, Kevin D ; Diwanji, Madhavi ; Perez-Olle, Raul ; Silva Correia, Carlos Eduardo ; Evans, Linton T ; Lee, Ian Y ; Andrews, David W ; Zacharia, Brad E ; Boockvar, John A ; Hanft, Simon ; Gill, Brian J ; Wu, Julian ; Scott, Charles ; Quiñones-Hinojosa, Alfredo

Standard-of-care first-line therapy for patients with newly diagnosed glioblastoma (ndGBM) is maximal safe surgical resection, then concurrent radiotherapy and temozolomide, followed by maintenance temozolomide. IGV-001, the first product of the Goldspire™ platform, is a first-in-class autologous immunotherapeutic product that combines personalized whole tumor–derived cells with an antisense oligonucleotide (IMV-001) in implantable biodiffusion chambers, with the intent to induce a tumor-specific immune response in patients with ndGBM. Here, we describe the design and rationale of a randomized, double-blind, phase IIb trial evaluating IGV-001 compared with placebo, both followed by standard-of-care treatment in patients with ndGBM. The primary end point is progression-free survival, and key secondary end points include overall survival and safety.

01 Dec 2023·Journal of neuro-oncology

Targeted immunotherapy for glioblastoma involving whole tumor-derived autologous cells in the upfront setting after craniotomy

Review

Author: Andrews, David W ; Andrews, Carrie E ; Zilberberg, Jenny ; Perez-Olle, Raul ; Exley, Mark A

Abstract:

Purpose:

To date, immunotherapeutic approaches in glioblastoma (GBM) have had limited clinical efficacy as compared to other solid tumors. Here we explore autologous cell treatments that have the potential to circumvent treatment resistance to immunotherapy for GBM.

Methods:

We performed literature review and assessed clinical outcomes in phase 1 safety trials as well as phase 2 and 3 autologously-derived vaccines for the treatment of newly-diagnosed GBM. In one recent review of over 3,000 neuro-oncology phase 2 and phase 3 clinical trials, most trials were nonblinded (92%), single group (65%), nonrandomized (51%) and almost half were GBM trials. Only 10% involved a biologic and only 2.2% involved a double-blind randomized trial design.

Results:

With this comparative literature review we conclude that our autologous cell product is uniquely antigen-inclusive and antigen-agnostic with a promising safety profile as well as unexpected clinical efficacy in our published phase 1b trial. We have since designed a rigorous double-blinded add-on placebo-controlled trial involving our implantable biologic drug device. We conclude that IGV-001 provides a novel immunotherapy platform for historically intransigent ndGBM in this ongoing phase 2b trial (NCT04485949).

01 Apr 2021·Clinical cancer research : an official journal of the American Association for Cancer ResearchQ1 · MEDICINE

Phase Ib Clinical Trial of IGV-001 for Patients with Newly Diagnosed Glioblastoma

Q1 · MEDICINE

Article

Author: Prosniak, Mikhail ; Kenyon, Lawrence ; Ye, Donald Y. ; Garcia, Samantha ; Kim, Lyndon ; Pigott, Kara ; Harshyne, Larry A. ; Werner-Wasik, Maria ; Flanders, Adam ; Shi, Wenyin ; Judy, Kevin D. ; Hooper, D. Craig ; Atsina, Kofi-Buaku ; Kean, Rhonda ; Curtis, Mark ; Bongiorno, Emily ; Liu, Haisong ; Andrews, David W. ; Exley, Mark A. ; Scott, Charles B. ; Talekar, Kiran ; Sauma, Sami ; Martinez, Nina

Abstract:

Purpose::

Despite standard of care (SOC) established by Stupp, glioblastoma remains a uniformly poor prognosis. We evaluated IGV-001, which combines autologous glioblastoma tumor cells and an antisense oligonucleotide against IGF type 1 receptor (IMV-001), in newly diagnosed glioblastoma.

Patients and Methods::

This open-label protocol was approved by the Institutional Review Board at Thomas Jefferson University. Tumor cells collected during resection were treated ex vivo with IMV-001, encapsulated in biodiffusion chambers with additional IMV-001, irradiated, then implanted in abdominal acceptor sites. Patients were randomized to four exposure levels, and SOC was initiated 4–6 weeks later. On the basis of clinical improvements, randomization was halted after patient 23, and subsequent patients received only the highest exposure. Safety and tumor progression were primary and secondary objectives, respectively. Time-to-event outcomes were compared with the SOC arms of published studies.

Results::

Thirty-three patients were enrolled, and median follow-up was 3.1 years. Six patients had adverse events (grade ≤3) possibly related to IGV-001. Median progression-free survival (PFS) was 9.8 months in the intent-to-treat population (vs. SOC, 6.5 months; P = 0.0003). In IGV-001–treated patients who met Stupp-eligible criteria, PFS was 11.6 months overall (n = 22; P = 0.001) and 17.1 months at the highest exposure (n = 10; P = 0.0025). The greatest overall survival was observed in Stupp-eligible patients receiving the highest exposure (median, 38.2 months; P = 0.044). Stupp-eligible patients with methylated O6-methylguanine–DNA methyltransferase promoter (n = 10) demonstrated median PFS of 38.4 months (P = 0.0008). Evidence of immune activation was noted.

Conclusions::

IGV-001 was well tolerated, PFS compared favorably with SOC, and evidence suggested an immune-mediated mechanism (ClinicalTrials.gov: NCT02507583).

News (Medical) associated with IGV-001

11 Nov 2024

·www.businesswire.com

Imvax to Present Safety Data on Lead Program, IGV-001, at 2024 SNO Annual Meeting

PHILADELPHIA--( BUSINESS WIRE )-- Imvax, Inc. , a clinical-stage biotechnology company developing personalized, whole-tumor derived immunotherapies, today announced an oral presentation and two poster presentations at the 2024 Society for NeuroOncology (SNO) 29 th Annual Meeting in Houston, Texas, from November 21-24, 2024. Separately, the Company will also host a symposium focused on the development of IGV-001 for the treatment of newly diagnosed glioblastoma. Imvax will present blinded safety data from the Company’s ongoing randomized, multicenter, double-blind, placebo-controlled Phase 2b clinical trial of IGV-001 in patients with newly diagnosed glioblastoma (ndGBM). The Phase 2b study to assess the safety and efficacy of IGV-001 in patients with ndGBM (NCT04485949) has completed enrollment and top-line results are expected to be presented in mid-2025. Imvax will also present follow-on data from its Phase 1b study of IGV-001 in patients with ndGBM, as well as preclinical data of IGV-001 in combination with checkpoint inhibitors. The details of the oral presentation and two poster presentations are below: Title: Early safety data from a randomized, multicenter, double-blind, phase 2b study of IGV-001, an autologous cell immunotherapy, versus placebo, in newly diagnosed glioblastoma (ndGBM) Number: CTIM-14 Timing: November 22, 7:25 p.m. – 7:35 p.m. CST Presenter: Brad Elder, M.D. Title: Long-term survivors from a Phase 1b study of IGV-001 in patients with newly diagnosed glioblastoma Number: CTIM-11 Timing: November 21-22, 7:30 p.m. – 9:30 p.m. CST Presenter: Raul-Perez Olle, M.D., Ph.D. Title: IGV-001: A biologic-device combination product elicits potent anti-GBM responses as a monotherapy and in combination with check point inhibition Number: IMMU-30 Timing: November 21-22, 7:30 p.m. – 9:30 p.m. CST Presenters: Jenny Zilberberg, Ph.D. & Mark A. Exley, Ph.D. On Friday, November 22, 2024, from 12:45 p.m. – 1:45 p.m. CST, Raul Perez-Olle, M.D., Ph.D., SVP, Head of Clinical Development and Medical Affairs at Imvax, Brad Zacharia, M.D., M.S., FAANS, Associate Professor of Neurosurgery and Otolaryngology at Penn State Health, and Brad Elder, M.D., Director, Neurosurgical Oncology, and Associate Professor, Department of Neurological Surgery at The Ohio State University Wexner Medical Center, will host a symposium, entitled “ Development of IGV-001 for the treatment of newly diagnosed glioblastoma,” focused on Imvax’s proprietary Goldspire ® platform and the development of IGV-001 for the treatment of ndGBM. Register for the session here . About IGV-001 IGV-001 is an autologous biologic-device combination product derived from Imvax’s proprietary Goldspire ® immuno-oncology platform for solid tumors, which involves a unique approach to inducing a broad and durable immune response against tumors. Phase 1 studies showed that IGV-001 was safe and well tolerated, and a Phase 1b ndGBM study also yielded several efficacy signals, including significant improvements in PFS, OS, radiographic evidence of tumor response, and multiple biomarker changes that supported the presence of an immune response (Andrews DW, et al., Clin Cancer Res. 2021;27(7):1912-1922). In ten Stupp-eligible ndGBM patients in the highest dose cohort treated with IGV-001, median PFS was 17.1 months, compared with 6.5 months in historical standard-of-care (SOC) treatment, and median OS was 38.2 months, compared with 16.2 months in historical SOC. About Imvax, Inc. Imvax is a clinical-stage biotechnology company with a unique platform technology, Goldspire ® , focused on delivering personalized, whole tumor-derived immunotherapies across a range of solid tumors. Imvax’s most advanced program, IGV-001, is currently being evaluated in a Phase 2b clinical trial in newly diagnosed glioblastoma patients. Imvax’s portfolio also includes several other programs designed to stimulate a patient’s immune system against the entire antigen signature of their tumor. Imvax is headquartered in Philadelphia, PA. For additional information, please visit www.imvax.com .

ImmunotherapyPhase 1ASCOPhase 2Clinical Result

21 May 2024

·www.biospace.com

Imvax Announces Completion of Enrollment in Phase 2b Clinical Trial of IGV-001 and Successful Financing

– Enrollment completed within planned timeframe of 14 months – – IGV-001 granted Fast Track designation by U.S. FDA – – $35 million financing completed in 2024 to fund operations beyond expected Phase 2b data readout in mid-2025 – PHILADELPHIA--(BUSINESS WIRE)-- Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, today announced the completion of enrollment in its randomized, multicenter, double-blind, placebo-controlled Phase 2b clinical trial of IGV-001 in patients with newly diagnosed glioblastoma (ndGBM). IGV-001 is derived from Imvax’s proprietary Goldspire™ immuno-oncology platform, which is designed to use a patient’s own tumor cells to induce a broad and durable immune response against tumors. The primary endpoint of the Phase 2b trial is Progression Free Survival (PFS) and top-line data is expected by mid-2025. Separately, the Company today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to IGV-001 for the treatment of ndGBM based on the Company’s existing Phase 1b data supporting its therapeutic potential in this underserved and life-threatening condition. Imvax also announced the closing of an approximately $35 million financing round, with half of the capital coming from new investors. Over the past 15 months, the Company has raised $57 million to support the completion of the Phase 2b trial. “We are very pleased to announce full enrollment of the trial in less than 14 months, which speaks to both the clinical interest in this potential therapy and the efficient execution of our novel approach to treating GBM patients,” said John P. Furey, Chief Executive Officer. “We are grateful to the investigators, patients, and their families for their commitment to this study and look forward to seeing top-line data next year. We are also delighted that the FDA has granted Fast Track designation to IGV-001. The last significant advancement in the standard of care for GBM – about an 8-week improvement in PFS – was nearly 20 years ago, highlighting the need for continued innovation and treatment options. We believe IGV-001 may offer meaningful clinical benefit for patients diagnosed with this deadly disease.” Mr. Furey continued, “We are grateful for the support of both existing and multiple new investors in our recent fundraising, which reflects their belief in the promise of IGV-001 and their commitment to patients facing a GBM diagnosis. We now have sufficient resources to support the completion of the trial and carry us beyond the reporting of top-line results in mid-2025.” About the Phase 2b Trial The Phase 2b clinical trial is a randomized, multicenter, double-blind, placebo-controlled study (NCT04485949) designed to assess the safety and efficacy of IGV-001, an autologous biologic-device combination product, in ndGBM patients. The trial enrolled approximately 100 participants in a 2:1 randomization across 20 sites in the United States. Approximately 48 hours after surgical resection, participants in the IGV-001 arm were implanted with biodiffusion chambers containing a combination of personalized whole tumor-derived cells with an antisense oligonucleotide (IMV-001); in the placebo arm, the chambers contained an inactive solution only. In both arms, the biodiffusion chambers were explanted approximately 48 hours later, and after six weeks all patients were treated with standard of care (adjuvant radiotherapy and temozolomide followed by maintenance temozolomide). The primary endpoint of the trial is progression-free survival (PFS) and key secondary endpoints include overall survival (OS) and safety. About IGV-001 IGV-001 is an autologous biologic-device combination product derived from Imvax’s proprietary Goldspire™ immuno-oncology platform for solid tumors, which involves a unique approach to inducing a broad and durable immune response against tumors. Phase 1 studies showed that IGV-001 was safe and well tolerated, and a Phase 1b ndGBM study also yielded several efficacy signals, including significant improvements in PFS, OS, radiographic evidence of tumor response, and multiple biomarker changes that supported the presence of an immune response (Andrews DW, et al., Clin Cancer Res. 2021;27(7):1912-1922). In ten Stupp-eligible ndGBM patients in the highest dose cohort treated with IGV-001, median PFS was 17.1 months, compared with 6.5 months in historical standard-of-care (SOC) treatment, and median OS was 38.2 months, compared with 16.2 months in historical SOC. About Fast Track Designation Fast Track is a process designed by the FDA to facilitate the development and expedite the review of investigational treatments that have the potential to treat serious conditions and address recognized areas of unmet medical need. Programs with Fast Track designation can benefit from early and more frequent interactions with the FDA to discuss the product candidate’s development plan in addition to a rolling submission of the marketing application. Product candidates with Fast Track designation also may be eligible for priority review and accelerated approval. About Imvax, Inc. Imvax is a clinical-stage biotechnology company with a unique platform technology, Goldspire™, focused on delivering personalized, whole tumor-derived immunotherapies across a range of solid tumors. Imvax’s most advanced program, IGV-001, is currently being evaluated in a Phase 2b clinical trial in newly diagnosed glioblastoma patients. Imvax’s portfolio also includes several other programs designed to stimulate a patient’s immune system against the entire antigen signature of their tumor. Imvax is headquartered in Philadelphia, PA. For additional information, please visit .

Phase 2Clinical ResultFast TrackImmunotherapyPhase 1

20 Nov 2023

·www.biospace.com

Imvax Presents New Data at 2023 SNO Annual Meeting Supporting its Lead Program, IGV-001, in Newly Diagnosed Glioblastoma

PHILADELPHIA--(BUSINESS WIRE)-- Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, today announced details of its two poster presentations at the 2023 Society for NeuroOncology (SNO) 28th Annual Meeting, which was held in Vancouver, British Columbia, Canada, from November 15-19, 2023. At the meeting, Imvax presented new data from its Phase 1b study of IGV-001 in patients with newly diagnosed glioblastoma (ndGBM). Ian Y. Lee, M.D., Neurosurgeon, Henry Ford Health System, also presented information relating to Imvax’s ongoing randomized, multicenter, double-blind, placebo-controlled Phase 2b clinical trial of IGV-001 in patients with ndGBM. “These presentations highlight the importance of the Phase 1b results to the IGV-001 program and reflect the rigor of the design of the ongoing Phase 2b trial,” said David W. Andrews, M.D., Chief Medical Officer of Imvax. “I’m pleased to report that the Phase 2b study is enrolling well, and we expect to complete enrollment in the first half of 2024.” The first poster presentation, entitled “Additional results from a Phase 1b study of IGV-001 in patients with newly diagnosed glioblastoma,” highlights a statistically significant correlation in Imvax’s Phase 1b study of IGV-001 between progression free survival (PFS) and overall survival (OS) in the intent-to-treat (ITT) study population, suggesting the use of median PFS as an end point in future ndGBM clinical trials. Additional data presented highlighted a significant decrease at various study points of the average neutrophil-to-lymphocyte (NLR) ratio. The NLR may be a potential biomarker for positive clinical outcomes, which will be further explored as part of Imvax’s ongoing Phase 2b study in ndGBM patients. The second poster presentation, entitled “A randomized, multicenter, double-blind, Phase 2b study of IGV-001, an autologous cell immunotherapy with antisense oligo IMV-001 targeting IGF-1R, vs placebo, in newly diagnosed glioblastoma patients,” described the ongoing Phase 2b trial (NCT04485949) including study objectives, design, endpoints, locations, and key inclusion and exclusion criteria. About IGV-001 IGV-001 is an autologous biologic-device combination product derived from Imvax’s proprietary Goldspire™ immuno-oncology platform for solid tumors, which involves a unique approach to inducing a broad and durable immune response against tumors. Phase 1 studies showed that IGV-001 was safe and well tolerated, and a Phase 1b ndGBM study also yielded several efficacy signals, including significant improvements in PFS, OS, radiographic evidence of tumor response, and multiple biomarker changes that supported the presence of an immune response (Andrews DW, et al., Clin Cancer Res. 2021;27(7):1912-1922). In ten Stupp-eligible ndGBM patients in the highest dose cohort treated with IGV-001, median PFS was 17.1 months, compared with 6.5 months in historical standard-of-care (SOC) treatment, and median OS was 38.2 months, compared with 16.2 months in historical SOC. About Imvax, Inc. Imvax is a clinical-stage biotechnology company with a unique platform technology, Goldspire™, focused on delivering personalized, whole tumor-derived immunotherapies across a range of solid tumors. Imvax’s most advanced program, IGV-001, is currently being evaluated in a Phase 2b clinical trial in newly diagnosed glioblastoma patients. Imvax’s portfolio also includes several other programs designed to stimulate a patient’s immune system against the entire antigen signature of their tumor. Imvax is headquartered in Philadelphia, PA. For additional information, please visit .

ImmunotherapyClinical ResultPhase 1ASCOPhase 2

100 Deals associated with IGV-001

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Glioblastoma	Phase 2	US	ImVax, Inc.Startup	20 Mar 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02507583 (IMMU-30, SNO2024)	Phase 1	Glioblastoma IGF-1R	10	mIGV-001	wglxxwxztc(hyixwojupe) = impepdgalm gglsyhyskn (vrnzbgpwgk )	Positive	11 Nov 2024
				IGV-001 (BDC placebo)	wglxxwxztc(hyixwojupe) = mecuhjouag gglsyhyskn (vrnzbgpwgk )
NCT04485949 (P12.09.A, EANO2024)	Phase 2	Glioblastoma IGF-1R mRNA	93	IGV-001	sjtognzeba(dkhukrsmpb) = dsptrwvsfl kuhlmjdzox (ekqsmvtlgv ) View more	Positive	17 Oct 2024
NCT02507583 (Pubmed \| Clin Cancer Res)	Phase 1	Glioblastoma	33	IGV-001	clsouaetkb(wvgmxvwjzc) = Six patients had adverse events (grade ≤3) possibly related to IGV-001 ohzfyhuliu (xpqrkweryg )	-	26 Jan 2021
				IGV-001 (Standard of care (SOC))
NCT02507583 (GlobeNewswire) Manual	Phase 1	Glioblastoma First line	33	Standard of Care+IGV-001	zidodqofhh(doeatvektu) = dyrudjdcea skqjrczcqx (nrudqgrprd ) View more	Positive	31 Mar 2019
				Standard of Care	zidodqofhh(doeatvektu) = orlvvlwleo skqjrczcqx (nrudqgrprd ) View more
IG-001 phase 4 data in Korea (AACR2014)	Phase 4	Metastatic breast cancer	186	IG-001	fnpfujysdf(qnwtzaszep) = drkdcdixua gbltwkqwcs (nlvemlilnz ) View more	Positive	01 Oct 2014
AACR2013	Not Applicable	Neoplasms	-	IG-001	botiwbnwaq(kndaprdmga) = hgxlwvbamt wyxmqoxxfs (psagnptwni ) View more	-	15 Apr 2013
				Taxol	botiwbnwaq(kndaprdmga) = vcpcbzqbea wyxmqoxxfs (psagnptwni ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

IGV-001

Overview

Basic Info

Gene Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation